CTI BioPharma
223 articles about CTI BioPharma
-
CTI BioPharma To Report Fourth Quarter And Full Year 2014 Financial Results On March 12, 2015
2/26/2015
-
Day in the Life of a CEO—Jim Bianco, CTI BioPharma
2/4/2015
-
CTI BioPharma Announces Independent DMC Recommendation To Continue GOG-0212 Phase 3 Study Of OPAXIO™ As Maintenance Therapy In Ovarian Cancer, An NRG Oncology/GOG Study
2/3/2015
-
VC Firm CTI BioPharma Collects $112 Million for New Biotech Fund
1/15/2015
-
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
1/12/2015
-
CTI BioPharma Announces 2015 Outlook And Recent Drug Portfolio Progress
1/8/2015
-
CTI BioPharma Announces Presentation Of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance In FLT3-ITD Positive AML Cells
12/9/2014
-
CTI BioPharma Announces Comprehensive Kinome Analysis That Demonstrates Pacritinib Inhibits Kinases Linked To A Spectrum Of Blood-Related Cancers
12/8/2014
-
CTI BioPharma Receives $15 Million Milestone Payment for TRISENOX
12/4/2014
-
CTI BioPharma Announces Data Presentations At The 56th American Society of Hematology Annual Meeting
12/1/2014
-
CTI BioPharma To Present At The Upcoming Investor Conferences
11/17/2014
-
CTI BioPharma Prices Underwritten Public Offering Of $35 Million Of Convertible Preferred Stock
11/7/2014
-
CTI BioPharma Announces Proposed Public Offering Of Convertible Preferred Stock
11/7/2014
-
CTI BioPharma Reports Third Quarter 2014 Financial Results
10/30/2014
-
Vernalis PLC Announces CTI BioPharma Becomes Worldwide Licensee For Tosedostat
10/27/2014
-
CTI BioPharma Grabs Exclusive Worldwide Rights To Tosedostat
10/27/2014
-
CTI BioPharma To Report Third Quarter 2014 Financial Results On October 29, 2014
10/20/2014
-
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize Pixuvri®
9/17/2014
-
CTI BioPharma Granted Fast Track FDA Status For Pacritinib
8/7/2014
-
CTI BioPharma Reports Second Quarter 2014 Financial Results
8/5/2014